hu14.18K322A

Phase 2Biologic

SSt. Jude Children's Research Hospital

hu14.18K322A is one of 80 biologic programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

NeuroblastomaActive, not recruiting

High-Risk NeuroblastomaRecruiting

LymphomaPhase 1

Active, not recruiting

NeuroblastomaPhase 2

Active, not recruiting

High-Risk NeuroblastomaPreclinical

Recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Oncaspar

SServier

Preclinical

15 3

Norvir

AbbVie

Preclinical

1 4

hu14.18K322A

SSt. Jude Children's Research Hospital

Phase 2

1 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Tafasitamab

Incyte

Preclinical

7 7

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Nuvigil

NNuvo Research GmbH

Preclinical

1 9

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 10

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Recruiting

Neuroblastoma

NCT07085338

Q1 2031

PreclinicalRecruiting

High-Risk Neuroblastoma

NCT07549321

Clinical

Trials by Indication[1]

Neuroblastoma2 trials

Therapy for Children With Advanced Stage Neuroblastoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01857934·153 enrolled

A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT07085338·54 enrolled

Lymphoma1 trial

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT02130869·8 enrolled

High-Risk Neuroblastoma1 trial

A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination With Chemotherapy in Participants With High-Risk Neuroblastoma

Recruiting·RRenaissance Pharma Ltd.·Preclinical·NCT07549321·144 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for hu14.18K322A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — hu14.18K322A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for hu14.18K322A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Jude Children's Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: SSt. Jude Children's Research Hospital

hu14.18K322A

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q1 2031

Trials by Indication[1]

Neuroblastoma2 trials

Lymphoma1 trial

High-Risk Neuroblastoma1 trial

References

Drug Info

Quick Facts

Related News